| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology and Genetics |
Departments of 1 Medicine and 2 Psychiatry, Pediatrics, and Human Genetics; Committees on 3 Clinical Pharmacology and Pharmacogenomics and 4 Cancer Biology; and 5 Cancer Research Center, University of Chicago, Chicago, Illinois
Requests for reprints: Mark J. Ratain, University of Chicago, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637. Phone: 773-702-4400; Fax: 773-702-3969; E-mail: mratain{at}medicine.bsd.uchicago.edu
The epidermal growth factor receptor (EGFR) plays a prominent role in cell growth and development. Its regulation in humans is complex and incompletely understood. In this study, 12 new polymorphisms were discovered in the 5'-regulatory region of EGFR gene and 2 common single nucleotide polymorphisms (–216G/T and –191C/A) were found in the essential promoter area, one of which is located in a Sp1 recognition site (–216). Transient transfection in human cancer and primary cell lines showed significantly different promoter activity between the two most common haplotypes (–216G-191C and –216T-191C). The replacement of G by T at position –216 increases the promoter activity by 30%. A transient transfection assay in the Sp1-deficient cell line (Schneider cell line 2) showed a strong dependence of EGFR promoter activity on Sp1 and confirmed the effect of the aforementioned polymorphisms. Electrophoretic mobility shift assay also showed a significantly higher binding efficiency of nuclear protein or pure Sp1 protein to the T allele compared with the G allele. We then investigated the allelic imbalance of EGFR transcription in fibroblast cell lines with heterozygous genotype at –216G/T but C/C homozygous genotype at –191C/A. The expression of mRNA carrying T-C haplotype was significantly stronger compared with that of G-C haplotype (P < 0.02). Thus, we successfully showed that a common polymorphism in the EGFR promoter was associated with altered promoter activity and gene expression both in vitro and in vivo. Our findings have implications for cancer etiology and therapy and may also be relevant to the inherited susceptibility of other common diseases.
Key Words: EGFR • single nucleotide polymorphism • Sp1 • promoter
This article has been cited by other articles:
|
|
 |
|
  K. -L. Garm Spindler, N. Pallisgaard, A. A. Rasmussen, J. Lindebjerg, R. F. Andersen, D. Cruger, and A. Jakobsen The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer Ann. Onc., May 1, 2009; 20(5): 879 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-S. Hong, S. L. Deming, Y.-T. Gao, J.-R. Long, X.-O. Shu, Q. Cai, W. Lu, and W. Zheng A Two-stage Case-Control Study of EGFR Polymorphisms and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 680 - 683. [Full Text] [PDF]
|
|
|
|
|
|
G. Milano, M.-C. Etienne-Grimaldi, L. Dahan, M. Francoual, J.-P. Spano, D. Benchimol, M. Chazal, C. Letoublon, T. Andre, F.-N. Gilly, et al. Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer Ann. Onc., December 1, 2008; 19(12): 2033 - 2038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Bell, B. W. Brannigan, K. Matsuo, D. M. Finkelstein, R. Sordella, J. Settleman, T. Mitsudomi, and D. A. Haber Increased Prevalence of EGFR-Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms Clin. Cancer Res., July 1, 2008; 14(13): 4079 - 4084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Graziano, A. Ruzzo, F. Loupakis, E. Canestrari, D. Santini, V. Catalano, R. Bisonni, U. Torresi, I. Floriani, G. Schiavon, et al. Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer J. Clin. Oncol., March 20, 2008; 26(9): 1427 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Rudin, W. Liu, A. Desai, T. Karrison, X. Jiang, L. Janisch, S. Das, J. Ramirez, B. Poonkuzhali, E. Schuetz, et al. Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity J. Clin. Oncol., March 1, 2008; 26(7): 1119 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rokavec, C. Justenhoven, W. Schroth, M. A. Istrate, S. Haas, H.-P. Fischer, C. Vollmert, T. Illig, U. Hamann, Y.-D. Ko, et al. A Novel Polymorphism in the Promoter Region of ERBB4 Is Associated with Breast and Colorectal Cancer Risk Clin. Cancer Res., December 15, 2007; 13(24): 7506 - 7514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Liu, X. Wu, W. Zhang, R. C. Montenegro, D. L. Fackenthal, J. A. Spitz, L. M. Huff, F. Innocenti, S. Das, E. H. Cook, Jr., et al. Relationship of EGFR Mutations, Expression, Amplification, and Polymorphisms to Epidermal Growth Factor Receptor Inhibitors in the NCI60 Cell Lines Clin. Cancer Res., November 15, 2007; 13(22): 6788 - 6795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-S. Wang, P.-M. Chen, T.-J. Chiou, J.-H. Liu, J.-K. Lin, T.-C. Lin, H.-S. Wang, and Y. Su Epidermal Growth Factor Receptor R497K Polymorphism Is a Favorable Prognostic Factor for Patients with Colorectal Carcinoma Clin. Cancer Res., June 15, 2007; 13(12): 3597 - 3604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Araujo, R. Ribeiro, I. Azevedo, A. Coelho, M. Soares, B. Sousa, D. Pinto, C. Lopes, R. Medeiros, and G. V. Scagliotti Genetic Polymorphisms of the Epidermal Growth Factor and Related Receptor in Non-Small Cell Lung Cancer--A Review of the Literature Oncologist, February 1, 2007; 12(2): 201 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S-H. Ou, J. Zell, A Ziogas, and H Anton-Culver Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology Ann. Onc., January 1, 2007; 18(1): 29 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Brandt, S. Meyer-Staeckling, H. Schmidt, K. Agelopoulos, and H. Buerger Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response Clin. Cancer Res., December 15, 2006; 12(24): 7252 - 7260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cusatis, V. Gregorc, J. Li, A. Spreafico, R. G. Ingersoll, J. Verweij, V. Ludovini, E. Villa, M. Hidalgo, A. Sparreboom, et al. Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib J Natl Cancer Inst, December 6, 2006; 98(23): 1739 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Carpentier, F. Laigle-Donadey, Y. Marie, N. Auger, A. Benouaich-Amiel, J. Lejeune, G. Kaloshi, J. -Y. Delattre, J. Thillet, and M. Sanson Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma Neurology, September 12, 2006; 67(5): 872 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Higashi, S. Kyo, M. Inoue, H. Tanii, and K. Saijoh Novel Functional Single Nucleotide Polymorphisms in the Latent Transforming Growth Factor-{beta} Binding Protein-1L Promoter: Effect on Latent Transforming Growth Factor-{beta} Binding Protein-1L Expression Level and Possible Prognostic Significance in Ovarian Cancer J. Mol. Diagn., July 1, 2006; 8(3): 342 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E.W. Cohen Role of Epidermal Growth Factor Receptor Pathway-Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., June 10, 2006; 24(17): 2659 - 2665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Calvo and J. Baselga Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors J. Clin. Oncol., May 10, 2006; 24(14): 2158 - 2163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Albertini, A. Jain, S. Vignati, S. Napoli, A. Rinaldi, I. Kwee, M. Nur-e-Alam, J. Bergant, F. Bertoni, G. M. Carbone, et al. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Res., January 1, 2006; 34(6): 1721 - 1734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E.W. Cohen, M. A. Kane, M. A. List, B. E. Brockstein, B. Mehrotra, D. Huo, A. M. Mauer, C. Pierce, A. Dekker, and E. E. Vokes Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., December 1, 2005; 11(23): 8418 - 8424. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
